Andrew Guggenhime sold $632K of Vaxcyte (PCVX)

Executed Jan 21 2025, disclosed Jan 22 2025, 1 day later.

Value, as filed

$632K

7,317 sh across 2 lots

Executed

Jan 21 2025

the trade date, as filed

Disclosed

Jan 22 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Andrew Guggenhime PRESIDENT AND CFO profile →

Andrew Guggenhime (PRESIDENT AND CFO) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Vaxcyte, Inc. (PCVX). The largest single filing was $573K of PCVX (10,000 sh across 2 lots, as filed), executed Jul 6.

The name

PCVX

Vaxcyte, Inc. PCVX · Healthcare · 41 filings in 24 months ticker →

Healthcare · Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial inf…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Andrew Guggenhime in PCVX

PCVXSALE Vaxcyte, Inc. $539K
10,000 sh across 2 lots
Exec Aug 3
Filed Aug 5 · 4:58 PM ET PCVXSALE Vaxcyte, Inc. $573K
10,000 sh across 2 lots
Exec Jul 6
Filed Jul 6 · 7:31 PM ET PCVXSALE Vaxcyte, Inc. $530K
10,000 sh × $53.00
Exec Jun 18
Filed Jun 18 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $671K
8,000 sh across 2 lots
Exec Feb 18 2025
Filed Feb 19 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $685K
7,720 sh across 3 lots
Exec Dec 18 2024
Filed Dec 19 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $675K
7,868 sh across 2 lots
Exec Nov 18 2024
Filed Nov 19 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $4.8M
42,000 sh across 2 lots
Exec Oct 18 2024
Filed Oct 22 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. $830K
7,171 sh across 2 lots
Exec Sep 18 2024
Filed Sep 19 2024 · 5:30 PM ET